Imagyn starts sales of Site Select
Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site
Imagyn Medical Technologies of Newport Beach, CA, last month concluded U.S. beta trials for its Site Select breast biopsy device. The company began the trials at 21 sites in September and, with their completion, has begun to market the device. Site Select allows physicians to locate and extract a biopsy specimen in one step. When the device is used with a stereotactic table, biopsies can be done with local anesthesia on an outpatient basis.